Past Performers

Affinium Pharmaceuticals Inc. Pharmaceuticals Inc. logo

Affinium Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of novel anti-infective medicines stemming from the bacterial fatty acid synthesis (FAS) II pathway.  The Company's lead compound, AFN-1252, is a highly potent small molecule antibiotic for both oral and IV treatment of staphylococcal infections including drug-resistant MRSA.  February 2014, Acquired by Debiopharm. 

DELEX Therapeutics Inc. Therapeutics Inc. logo

DELEX is a specialty pharmaceutical company focused on the development and commercialization of proprietary, controlled-release drugs. May 2005, Acquired by YM Biosciences (AMEX: YMI, TSX: YM, AIM: YMBA)

Epocal Inc. Inc. logo

Epocal's core expertise and enabling technologies are in the field of biochip nanotechnology. The company's biochips combine aspects of two powerful analytical technologies of the current state of the art, lab-on-a-chip microfluidic technology and microarray technology, into a more powerful integrated technology: solid-state fluidics.  February 2013, Acquired by Alere Inc. (NYSE: ALR)

Excel-Tech Limited Limited logo

XLTEK is a manufacturer of high-end medical instruments for the diagnosis and monitoring of patients over broadband networks. November 2007, Acquired by Natus Medical (NASD: BABY)

Ionalytics Corporation Corporation logo

Ionalytics is a developer and provider of a novel front-end separation device for mass spectrometry applications in the fields of proteomics and drug discovery. August 2005, Acquired by Thermo Electron Corporation (NYSE: TMO)

Millenium Biologix Corporation Biologix Corporation logo

Millenium Biologix Corporation is a leading therapeutic biomaterials company developing and supplying innovative products in the field of skeletal disease and trauma for clinical and research markets. April 2007, Acquired by Medtronic (NYSE: MDT)

Naurex Inc.http://www.naurex.comNaurex Inc. logo

Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR).

Naurex was acquired by Allergan August 2015 (NYSE: AGN)

Systems Xcellence Inc. Xcellence Inc. logo

Systems Xcellence (TSX:SXC) combines web-enabled, real time transaction processing technology with business consulting expertise and technical services to deliver patient-centered software solutions in the healthcare industry. (Divested via public markets)

Xillix Technologies Corporation Technologies Corporation logo

Xillix Technologies Corp. (TSX:XLX) is focused on the research, development and commercialization of medical imaging technologies which aid in the early detection and localization of cancer. (Divested via public markets)